Innocoll Holdings plc is using CollaRx technology
platform for the development of INL-001 for the treatment of post-operative pain.
The CollaRx technology platform produces a lyophilized porous matrix of
purified collagen that can be implanted at the time of surgery or applied
topically to chronic or acute traumatic wounds.
Access
Detailed Report Summary at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis
The CollaRx
matrices are biodegradable and bio-resorbable. The in vivo release of drugs
incorporated into the CollaRx matrix takes place via a combination of
dissolution, diffusion and the interactive characteristics of the active drug
and the formulation that can be modified to affect controlled release.
Download Report
Sample at: https://www.psmarketresearch.com/market-analysis/post-operative-pain-therapeutics-pipeline-analysis/report-sample
Some of the key players developing drugs for
post-operative pain include DURECT Corporation, Elite Pharmaceuticals, Inc.,
Cara Therapeutics, Inc. and others.
Make
Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=post-operative-pain-therapeutics-pipeline-analysis
Contact:
Mr. Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +18887787886
(USA/Canada)
Email: enquiry@psmarketresearch.com
No comments:
Post a Comment